← Back to headlines
Market Analysis: Novo Nordisk and Eli Lilly Battle for Weight-Loss Drug Dominance
Financial analysts question whether the GLP-1 weight-loss medication sector is truly a winner-take-all duopoly or if broader market dynamics favor multiple competitors.
24 Aug, 18:29 — 24 Aug, 18:29
Sources
Showing 1 of 1 sources
